Urticaria

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
ATC code not specified 2
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
Unknown / small molecule 1 substance
Phase III: 1 Phase I (Other): 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Celldex Therapeutics Inc. Commercial
    BARZOLVOLIMAB; EPINEPHRINE
    2025-522583-32-00 4 countries 2026 n=126
    Recruiting

Phase I (Other)

2 trials
  • Noucor Health S.A. Commercial
    IMP not specified
    2022-500774-34-00 2 countries 2022 n=44
    Ended
  • Noucor Health S.A. Commercial
    IMP not specified
    2022-500775-31-00 2 countries 2022 n=48
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Noucor Health S.A. Commercial 2 Phase I (Other) 0
Celldex Therapeutics Inc. Commercial 1 Phase III 1
New trials by year
2022
2
2026
1
← All indication landscapes